Abstract
Objective To explore the value of calcium dobesilate and acarbose in the treatment of diabetic retinopathy with cataract. Methods From January, 2017 to December, 2018, 86 patients (111 eyes) with diabetic retinopathy and cataract treated in our hospital were selected as clinical research subjects. By randomized digital table method, the patients were divided into an observation group with 44 cases (57 eyes) and a control group with 42 cases (54 eyes). The control group were treated with acarbose, and the observation group with calcium dobesilate and acarbose. The clinical treatment, the changes of inflammatory factors, and the occurrence of adverse reactions ofthe two groups were compared and analyzed. Results The total effective rate was 91.23% (52/57) and the ineffective rate was 8.77% (5/57) in the observation group, which were better than those in the control group (P 0.05). Conclusions Calcium dobesilate combined with acarbose could improve the efficacy and safety of clinical treatment by regulating the levels of cellular inflammatory factors. Key words: Diabetes; Retinopathy; Cataract; Calcium dobesilate; Acarbose
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
